

TOPIC	QUESTION	ESSENTIAL KNOWLEDGE	NOTES
Question 1: First Pass effect	<p>1. What is first pass effect? Prompt “Can you define first pass effect?”</p> <p>2. How can the first pass effect be reduced?</p>	<p>After absorption of an orally ingested drug, portal blood delivers drug to liver. *Metabolised in gut wall. *Metabolised in portal blood. *Metabolised by liver. *Excreted into bile</p> <p>Fraction of unchanged drug reaching systemic circulation may be reduced. ie. Reduces bio-availability of a drug</p> <p>Different route of administration IV; IM/SC; Sublingual; Transdermal; PR – Still may have some first pass metabolism, only 50% bypasses liver; Inhalational (may have first pass effect in the lung). Intrathecal (Class: Nitroimidazole antiprotozoal drug.) Pharmacokinetics: Well absorbed orally; Oral/IV/suppository (99% oral bio-availability); Metabolised in liver (can accumulate in hepatic insufficiency) and excreted in kidney; Low protein binding (10-20%); Dosage: 500mg tds or single dose of 2g for vaginitis; Half life 7.5 hours</p>	Pass: basic definition Mention 4 alternative routes Need 3 out of 6 PK
Question 2: Metronidazole	<p>1. Describe the pharmacokinetics of metronidazole</p> <p>2. What are the adverse effects of metronidazole?</p>	<p>Nausea, diarrhoea, dry mouth, hairy black tongue Headache, paraesthesia, dizziness, insomnia Dysuria, dark urine, Disulfiram-like effect, hence avoid alcohol Potentiate the effect of coumarin anticoagulants, Lithium Teratogenic effect on mice, but not proven in human</p> <p>Block amine (NA or Serotonin) reuptake pumps at presynaptic nerve endings prolongs duration of action of neurotransmitters at postsynaptic receptors. Most non selective</p>	Need 3 out of 6 categories Need 3 out of 6 categories
Question 3: Tricyclic antidepressants	<p>1. What is the mechanism of action of the tricyclic antidepressants? Prompt: Name one amine? “Where does it happen?”</p> <p>2. Describe the toxic effects in overdose and how are they mediated?</p>	<p>Antimuscarinic, tachycardia, dry mouth, blurred vision, delirium, coma, Agitation; Urinary retention, reduced gastric motility, Respiratory depression; Neuromuscular irritability and seizures Sympathomimetic: tremor, Insomnia Sedation: additive effects alpha 1-antagonist – postural hypotension, Hypotension, dizziness fast sodium-channel blockade – reduced myocardial contractility, QT prolongation, cardiac arrhythmias;</p>	Amine block, reuptake inhibitor some antimuscarinic cardiac (mix) Na channel block effects

<p>Question 4: Sulfonylureas</p> <p>1. What are the mechanisms of action of the Sulfonylureas? Prompt: How do sulphonylureas lower glucose? Describe another mechanism?</p> <p>3. What are the adverse effects of sulfonylurea therapy?</p>	<p>Increased secretion of insulin - Bind to pancreatic B cell receptor causing increased release of Insulin -Reduced serum glucagon levels – with chronic use thought to be due to indirect inhib effect of insulin and somatostatin on a cells -Potentiation of insulin action on target tissues – increased binding of insulin to tissue receptors ?due to indirect effect of reduced glycemia or FFA levels</p> <p>Prolonged hypoglycemia; Alcohol intolerance – flushing; Dilutional hyponatraemia (genetic predisposition) Jaundice, Leucopenia, thrombocytopenia (Chlorpropamide)</p> <p>Hypoglycaemia</p>
---	---

<p>Question 5: Laxatives</p> <p>1. Using examples, outline the mechanism of action of the various types of laxative?</p> <p><i>Prompt: How does X work for example</i></p>	<p>Irritants or Stimulants - (act early) castor oil -(act late)cascara, <u>senna</u>, aloe's (contain emodin alkaloids which are liberated after absorption from the intestine and excreted in the colon) -(prolonged action by enterohepatic circulation) phenolphthalein & bisacodyl</p> <p>Bulking agents -hydrophilic colloids, agar, psyllium seed, <u>bran</u></p> <p>Osmotic -magnesium citrate and magnesium hydroxide, polyethylene glycol, sorbitol, <u>lactulose</u></p> <p>Stool softeners; agents that emulsify with the stool and soften it (mineral oil, <u>glycerine</u>, detergents such as docosate (dioctyl sodium sulphosuccinate)</p>
---	---

TOPIC	QUESTION	ESSENTIAL KNOWLEDGE	NOTES
Question 1: Efficacy and Potency	<p>1. What is the difference between Efficacy and Potency?</p> <p>Prompt: You can draw a diagram if you like?</p> <p>2. What factors affect a drug's efficacy?</p>	<p>Potency: the concentration (EC_{50}) or dose (ED_{50}) of a drug required to produce 50% of that drug's maximal effect.</p> <p>Efficacy: the maximal effect that a drug exerts.</p> <p>Affinity of receptor for drug; the drug-receptor interaction . The route of administration, absorption, distribution through the body, and clearance from the blood or site of action</p>	<p>Definitions to pass</p> <p>Examiner note: Drugs A and B are more potent than drugs C and D because of the relative positions of their dose-response curves along the dose axis. Drugs A, C, and D have equal maximal efficacy, while all have greater maximal efficacy than drug B.</p> <p>3 out of 6 to pass (NB not to do with potency)</p>
Question 2: Cephalosporins	<p>1. How are the cephalosporins classified and give examples?</p> <p>Prompt:</p> <p><i>What are the different antimicrobial spectrums of the generations?</i></p> <p>2. What are the adverse effects of the Cephalosporins?</p>	<p>1st-gen: (cephalexin, cephazolin, cephalothin) very active against GPC (pneumococci, strep, and staph). GN org (<i>E. coli</i>, <i>K. pneumoniae</i>, & <i>Proteus mirabilis</i>) often sensitive, but not against GN aerobes (<i>P. aeruginosa</i>, indole-positive proteus, enterobacter, <i>Serratia marcescens</i>, citrobacter), & acinetobacter.</p> <p>2nd-gen: (cefaclor, cefamandole, cefuroxime) active against organisms inhibited by 1st-gen drugs, but have extended GN coverage. Klebsiella are usually sensitive. Some anaerobic</p> <p>3rd-gen agents (cefotaxime, ceftazidime, ceftriaxone) have expanded GN coverage & X BBB. Less active against staphy than earlier cephalosporins but are active against citrobacter, <i>S. marcescens</i>, & providencia. Also effective against β-lactamase-producing strains of <i>haemophilus</i> & <i>neisseria</i>. Some anaerobic</p> <p>None above active against MRSA, enterococci or <i>P. aeruginosa</i>.</p> <p>4th see next column</p>	<p>Know there are 4 generations, and understand principles of 3 of these</p> <p>4th-gen: (Cefepime) extended spectrum of activity covering the majority of the enteric GNPs, including <i>Pseudomonas</i> and Enterobacter. Also active against <i>S. aureus</i>, &<i>S. pneumoniae</i>. More resistant to hydrolysis by chromosomal β-lactamases (eg, those produced by enterobacter).</p> <p>Essential penicillin cross reactivity + 2 others</p> <p>Hypersens reactions identical to penicillins: anaphylaxis, fever, skin rashes, nephritis, granulocytopenia, & hemolytic anemia. Some individuals with a history of penicillin allergy may tolerate cephalosporins. Frequency of cross-allergenicity uncertain, probably around 5-10%. Severe pain IMI. Thrombophlebitis IVI. Renal toxicity: interstitial nephritis & ATN. Cephalosporins with a methylthiotetrazole group (eg, cefamandole, cefotetan) may cause: hypoprothrombinemia, bleeding (preventable with Vit K₁ 10 mg twice weekly) and severe disulfiram-like reactions with alcohol.</p>

<p>Question 3:</p> <p>SSRIs</p>	<p>1. What is the mechanism of action of the SSRIs <i>Prompt selective serotonin reuptake inhibitors</i> <i>Prompt for delayed onset of action- possible mechanisms?</i></p> <p>2. What receptor/channel effects lead to the SSRI side effect profile <i>Prompt why are SSRIs safer than TCAs?</i></p>	<p>General understanding knowledge of amine hypothesis and b) delayed inhibition ? > serotonin response ii.) Prolonged synaptic exposure to Serotonin leads to prob time frame 3-6 weeks due to presynaptic/ post synaptic receptor / storage regulation iv) SSRIs v HT specific v TCA 300-7000:1</p> <p>Very specific for HT (partic 1) receptors -therefore serotonin syndrome/ restlessness. Minimal autonomic NE activation + mild muscarinic / Na channel, H1 block effects (safety/ tolerance). Possibly some α block (sexual dysfunction)</p> <p>1). Absorption -complete all routes. Gut fast, resp tract slower- depends on mechanism delivery - gut 80% with Neb. 2). Metabolism- 50% 1st pass (less if IV) (sulphated- inactive) liver, rest renal/unchanged. 3). No resp metabolism. 4). t1/2 3-6hr – prolonged if resp pass</p> <p>1.Inhaled- Inhaler/ spacer: targeted/ low dose – minimal systemic ? local effects, co-ordination education, ii) Nebulised- less co-ord required> dose/systemic effects , noisy/frighten children- no benefit in co-ordinated patients 2.Oral- easier in v young/ disabled- longer t1/2, > SE profile, big doses, tachyphylaxis- possible increased deaths 3.IV/IM/SC – useful in asthma extremis or other indications, less 1st pass/. IV- pain/cost/staff use/high SE profile + high risk pts</p>
<p>Question 4:</p> <p>Salbutamol</p>	<p>1). Describe the pharmacokinetics of salbutamol? 2). What are the pros and cons of the different routes of delivery <i>Prompt: MDI vs nebuliser</i></p>	<p>Grasp of 2 different routes Inhaler/ spacer v Neb v IV minimum. Targeted proven effectiveness inhalers/pacers SE profile: <to > Inh v Neb v Oral v Systemic Co-ordination/delivery in extremis (age or severity) important</p>
<p>Question 5:</p> <p>Thioamides</p>	<p>1. How does carbimazole act in thyroid disease? 2. What are the major side effects of carbimazole? 3. How does carbimazole differ from propylthiouraci?</p>	<p>Bold to pass</p> <p>Metabolised to methimazole: Major action block hormone synthesis T3 and T4 Inhibits thyroid peroxidase – limits organification of iodine. Also blocks coupling of iodotyrosines Small action in blocking peripheral deiodination of T3 and T4. Slow onset as T4 may takes weeks to become depleted</p> <p>Rash maculopapular, pruritus – common; Bone marrow suppression: neutropenia, agranulocytosis (reversible). Others – urticaria, arthralgia, lupus reaction, vasculitis, jaundice/hepatitis; nausea and GI, occur early</p> <p>Carbimazole is a prodrug - converted to methimazole in vivo. Methimazole is 10 times more potent And one of the areas below</p> <ol style="list-style-type: none"> PTU has greater action in inhibiting peripheral deiodination of T4 and T3 Propylthiouracil is strongly protein bound: preferred in pregnancy; not secreted in breast milk PTU has shorter half life 1.5 vs 6 hours. PTU given qid, Carbimazole is daily PTU bioavail 50-80%, vs Carb 100% Vd = TBW) PTU excreted in urine as glucuronide metabolite <24 hours, carb in 48+ hours) <p>Bonus marks</p>

TOPIC	QUESTION	ESSENTIAL KNOWLEDGE	NOTES
Question 1: P450 enzyme system	<p>1. What is the role of the cytochrome P450 enzyme system?</p> <p><i>Prompt: what does CP450 do?</i></p> <p>2. What is the mechanism of CP450 enzyme induction and give examples?</p>	<p>Part of biotransformation system to detoxify drugs/substrates</p> <p>Acts by oxidation (phase 1 reaction): one molecule of oxygen is consumed per molecule of substrate</p> <p>Makes substrates more polar – easier to excrete or conjugate (phase2).</p> <p>Located on smooth endoplasmic reticulum</p> <p>Acts on a large number of lipophilic substrates, low specificity</p> <p>Relies on two enzymes: cytochrome P450, CP450 reductase (plus oxygen, NADPH). CP450 is a hemo-protein – active in the oxidized -ferric state- Fe³⁺</p> <p>Enhanced rate of synthesis - Reduced rate of degradation of CP450 enzyme</p> <p>Specific enzyme inducers eg:</p> <p>CYP/CP 450 2B1 - barbiturates</p> <p>CP 450 3A -steroids, macrolides, anticonvulsants</p> <p>CP 450 2E1 – isoniazid, chronic ethanol</p> <p>CP 450 1A1 – pollutants – aromatic hydrocarbons in tobacco smoke</p>	<p>Bold to pass</p> <p>1 mechanism and 2 examples</p>
Question 2: Gentamicin	<p>1. Describe the mechanism of action of gentamicin?</p> <p>2. What are the benefits of once daily dosing?</p> <p><i>Prompt how does this improve clinical effectiveness?</i></p>	<p>Irreversible inhibitor of protein synthesis. Passive diffusion via porin channels across outer memb, then active transport into cytoplasm by O₂ dependant process; transmembrane electrochem gradient supplies the E, transport coupled to proton pump. Low extracellular pH & anaerobic conditions inhibits transport as reduces gradient; transport enhanced by cell wall active drugs eg penicillin. Binds 30S ribosome & inhibits protein synthesis by simultaneously: 1). Inducing misreading of mRNA thus producing non toxic protein; 2) interfere with initiation complex of peptide formation; 3) cause break up of polyosomes into non-functional monosomes</p> <p>Concentration dependant killing (at increased conc kill increased no of bacteria at a more rapid rate); post antibiotic effect (effect lasts longer than detectable serum levels); reduced toxicity (as toxicity is time & conc dependant –time above critical level will be longer with multi dose than single dose schedule); less nursing time; OPD therapy possible; convenience</p>	<p>Conc dependent kill + 1 other</p>

Question 3: Phenytoin	<p>1. Describe the pharmacokinetics of phenytoin?</p> <p><i>Prompt: what is the effect on action potentials?</i></p> <p>Weak acid pKa 8.3; oral abs almost complete 90%, with peak serum conc 3-12hrs later. Slow release formulation also.</p> <p>IMI: incomplete abs with drug precipitation in the muscle, fosPOK</p> <p>Highly plasma protein bound, metabolised to inactive metabolites with urinary excretion, < 2% exc unchanged in urine.</p> <p>Dose dependant kinetics: Vd 45L/70kg, t1/2 av 24 hours (conc dependant). Therapeutic level 10-20mg/L. Drug interactions via plasma protein binding or via enz induction (CYP2C19 & CYP2C9). Alters TFT results; reduced CL neonates; foetal hydantoin syndrome</p> <p>2. Describe the pharmacodynamics of phenytoin?</p> <p><i>Prompt: what is the effect on action potentials?</i></p>	<p>Block sodium channels & inhibits the generation of repetitive APs blocks sustained high frequency repetitive firing of APs). Preferential binding to & prolongation of the inactivated state of the Na channel (use dependant effect on Na conductance).</p> <p>Other electrolyte effects -alters K conductance; alters Ca conductance ad decreases Ca permeability, inhibits Ca influx therefore affecting neurotransmitter & hormone release; -interacts with membrane lipids ? stabilising membranes; -paradoxical excitatory in some neurones; -alters membrane potentials and the conc of amino acids; affects neurotransmitters NA, Ach & GABA. High conc inhibits serotonin and NA release, promotes uptake of DA & inhibits MAO activity.</p>	<p>Pass: highly protein bound and dose dependant kinetics</p> <p>Pass: Na channel, And one other effect</p>
Question 4: Metoclopramide	<p>1. Describe the mechanism of action of metoclopramide?</p> <p><i>Prompt: what receptor does it act on? What are the peripheral/central actions?</i></p> <p>2.. List the adverse effects of metoclopramide?</p>	<p>Dopamine antagonist (D2 receptors)</p> <p>Central – via anti - nauseant and anti - emetic effect on the Chemoreceptor Trigger Zone / area postrema)</p> <p>Peripheral – blockade of GI dopamine receptors allowing cholinergic smooth muscle stimulation</p> <ul style="list-style-type: none"> - increases oesophageal peristaltic amplitude - increases lower oesophageal sphincter pressure - enhances gastric emptying <p>Relate to central dopamine antagonist action</p> <ul style="list-style-type: none"> - restlessness, drowsiness, insomnia, anxiety, agitation - extrapyramidal effects – dystonias, akathisia, parkinsonian features. - risk of tardive dyskinesia with chronic use - hyperprolactinaemia (galactorrhoea, gynaecomastia, impotence, menstrual disorders) 	<p>Pass dopamine antagonist, peripheral & central action</p> <p>Extrapyramidal + 1</p>
Question 5: Flecainide	<p>1. What is flecainide's mechanism of action?</p> <p>2. Describe flecainide's pharmacokinetics.</p> <p>3. In which patients is it contraindicated?</p>	<p>Na channel blockade (class effect). Predominant action is to inhibit the fast, or sodium, channel which is largely responsible for the rapid upstroke of the myocardial action potential in cardiac conducting tissue</p> <p>Class IC action - – minimal effect on the Action Potential Duration and dissociates from the Na channel with slow kinetics. (no effect on QT interval)</p> <p>Decrease the rate of rise (V_{max}, phase 0) of the action potential with little effect on duration.</p>	<p>Na channel block, class 1C</p> <p>2 things</p> <p>Hypotension, LV dysfunction</p> <p>Any answer</p>